🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Health Concern

Cases of gonorrhoea are on the rise globally, with data suggesting more than 82 million instances each year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices currently available.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Data and Global Access

Based on findings published in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which involves a dual-drug approach. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared hope. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the disease for people and to halt the transmission of untreatable gonorrhoea globally.